The Cognitive Burden of "Being a Patient": Evaluating Mental Health and Treatment Complexity

Key Takeaways:

• Only 1 percent of patients describe their current quality of life as "Excellent."
• Nearly 24 percent report "much difficulty" or a total inability to manage feelings of depression, and over 28 percent struggle with anxiety.
• 37 percent of patients report high levels of worry regarding insurance approvals and access to treatments, while 32 percent are deeply concerned about their ability to pay for necessary medications.

For the clinician, a successful consultation is often measured by objective markers: stable C-reactive protein levels, clear skin, and radiographic evidence of slowed progression. However, for the 1,002 patients surveyed in the 2025 PsA In America survey, the experience of living with psoriatic arthritis (PsA) is defined by a profound "cognitive burden.”¹

This cognitive burden is a relentless mental and emotional tax necessitated by managing an unpredictable, multi-systemic, and often invisible disease. It is exacerbated by significant treatment complexity and a persistent disconnect between clinical metrics and the patient’s lived reality.

The invisible struggle: Quality of life and mental health

While clinicians focus on physical manifestations of PsA, patients are navigating a silent crisis of well-being. Data shows that only 1 percent of PsA patients describe their current overall quality of life (QoL) as "Excellent.”¹

Instead, the majority fall into the "Good" (43 percent) or "Fair" (34 percent) categories, with many reporting that their condition significantly impacts their sense of independence and emotional stability.¹

The mental health toll is stark. Nearly 46 percent of patients report a "significant" negative impact on their physical health, but the "invisible" psychological symptoms are equally pervasive. Patients frequently mention the weight of anxiety and depression, yet feel these are secondary concerns in the exam room.¹

As one patient noted, "Just because I look 'okay' does not mean I am...PsA affects mental as well as physical."¹

The constant effort to "mask" pain for the sake of social or professional circles further depletes cognitive reserves.

The unpredictability of symptom management

The cognitive burden is driven largely by the extreme volatility of PsA. Patients report a wide array of symptoms experienced within a single month, including:¹

• Fatigue – 90 percent
• Joint stiffness – 89 percent
• Brain fog – 71 percent
• Nail changes – 66 percent

This multi-symptom profile requires constant monitoring and decision-making. The unpredictability of flares makes long-term planning very difficult. More than 29 percent of patients experienced 10 or more flares in the past year.¹

This creates a state of perpetual "hyper-vigilance," where patients must constantly assess their "spoon" count (energy units) before committing to even basic tasks. One patient described the management of symptoms, doctor appointments, and medications as "playing wack-a-mole."¹

Treatment complexity and the clinical disconnect

The therapeutic landscape for PsA is increasingly complex. While a majority of patients (61 percent) currently use biologics, the path to finding the "right" treatment is often fraught with trial and error. Patients have a high level of awareness regarding treatment options, yet 32 percent still plan to speak to their doctor about changing their treatment plan in the next 6 months.¹

A significant source of patient frustration is the perceived clinical focus on lab results over symptomatic experience. Patients frequently express that stable blood work does not equate to a stable life.¹

One patient says: "He looks at my blood results and says, 'Well, your levels are stable'... he is not really listening to me and how I truly feel... he just focuses on my bloodwork results and tells me he will see me in 3 months."¹

This “medical gaslighting," as some patients term it, increases the cognitive load as patients feel they must "prove" their pain to receive adequate care.

Socioeconomic stressors as comorbidities

The burden of "being a patient" extends beyond the clinic into the household. Financial toxicity is a major concern:¹

• 32 percent of patients report high levels of worry regarding their ability to pay for medication
• 37 percent worry about navigating insurance approvals

When patients are forced to choose between living expenses and medical care, the resulting stress acts as a pro-inflammatory catalyst, further complicating the clinical picture.

Moving toward comprehensive care

To alleviate the cognitive burden of PsA, clinicians must look beyond the joints and skin. The data suggests a clear need for:

• Validation of "invisible" symptoms – Acknowledging fatigue and brain fog as primary, not secondary, symptoms.
• Integrated mental health support – Screening for anxiety and depression as part of routine PsA management.
• Collaborative goal setting – Moving beyond "stable labs" to focus on the patient's ability to participate in hobbies and maintain independence.

The first step toward a more empathetic and effective clinical outcome is to understand that the PsA patient is managing much more than just a disease, but complex mental and emotional symptoms that stem from their chronic condition.